Form 8-K - Current report:
SEC Accession No. 0000950170-25-029010
Filing Date
2025-02-27
Accepted
2025-02-27 16:04:40
Documents
13
Period of Report
2025-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xene-20250224.htm   iXBRL 8-K 57649
2 EX-99.1 xene-ex99_1.htm EX-99.1 206587
3 GRAPHIC img189401473_0.jpg GRAPHIC 20831
  Complete submission text file 0000950170-25-029010.txt   431064

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT xene-20250224.xsd EX-101.SCH 30841
15 EXTRACTED XBRL INSTANCE DOCUMENT xene-20250224_htm.xml XML 4688
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36687 | Film No.: 25678618
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)